The Clinical Trials Office (CTO) provides a centralized and comprehensive infrastructure for the conduct of clinical trials involving cancer patients at Huntsman Cancer Institute (HCI). The CTO has evolved substantially since 2003 to reflect the Cancer Center's commitment to enhancing clinical research and to address the increasingly complex regulatory environment associated with clinical trials. The CTO functions as a central administrative office for the implementation and conduct of internally and externally funded adult oncology studies and integrates with the Pediatric Trials Office located at Primary Children's Medical Center for studies of cancers in children. The goals of the CTO are to 1) support Cancer Center investigators with all aspects of protocol development, initiation, implementation, management, and clinical study coordination; 2) prepare and process all regulatory documents for submission to the Institutional Review Board, Protocol Review and Monitoring System (known as the Clinical Cancer Investigations Committee at HCI), Data and Safety Monitoring Committee, Food and Drug Administration (FDA), and other regulatory committees, as required by federal and University of Utah (U of U) policies; 3) negotiate budgets and contracts with study sponsors and the U of U Office of Sponsored Projects; 4) manage billing and collection of study finances; and 5) provide quality data to regulatory committees and sponsors. The CTO is internally organized into specialty functions: regulatory, finance, and coordination. These groups are assigned to support specific organ-based tumor groups matching the HCI multidisciplinary clinical model. An independent group with a separate reporting structure oversees compliance. The CTO currently employs 35 staff and two faculty involved in study coordination, study compliance, data management, finance, regulation, specimen processing and collection of samples, research nursing, administration, protocol writing, grant development, and investigational new drug filing with the FDA. The CTO Shared Resource is managed by the Cancer Center with supervision by the Clinical Research Executive Committee chaired by Sean Mulvihill, MD, Senior Director of Clinical Affairs. The Funds are requested from the CCSG to cover 4 percent ($109,171) of the proposed CTO Shared Resource budget.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA042014-23S1
Application #
8533401
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-05-01
Budget End
2013-04-30
Support Year
23
Fiscal Year
2012
Total Cost
$3,408
Indirect Cost
$1,128
Name
University of Utah
Department
Type
DUNS #
009095365
City
Salt Lake City
State
UT
Country
United States
Zip Code
84112
Warner, Echo L; Ding, Qian; Pappas, Lisa et al. (2017) Health Care Providers' Knowledge of HPV Vaccination, Barriers, and Strategies in a State With Low HPV Vaccine Receipt: Mixed-Methods Study. JMIR Cancer 3:e12
Affolter, Kajsa; Gligorich, Keith; Samadder, Niloy Jewel et al. (2017) Feasibility of Large-Scale Identification of Sessile Serrated Polyp Patients Using Electronic Records: A Utah Study. Dig Dis Sci 62:1455-1463
Fowler, Brynn; Samadder, N Jewel; Kepka, Deanna et al. (2017) Improvements in Colorectal Cancer Incidence Not Experienced by Nonmetropolitan Women: A Population-Based Study From Utah. J Rural Health :
Ou, Judy Y; Smits-Seemann, Rochelle R; Kaul, Sapna et al. (2017) Risk of hospitalization among survivors of childhood and adolescent acute lymphoblastic leukemia compared to siblings and a general population sample. Cancer Epidemiol 49:216-224
VanderLinden, Ryan T; Hemmis, Casey W; Yao, Tingting et al. (2017) Structure and energetics of pairwise interactions between proteasome subunits RPN2, RPN13, and ubiquitin clarify a substrate recruitment mechanism. J Biol Chem 292:9493-9504
Cohen, Adam L; Factor, Rachel E; Mooney, Kathi et al. (2017) POWERPIINC (PreOperative Window of Endocrine TheRapy Provides Information to Increase Compliance) trial: Changes in tumor proliferation index and quality of life with 7 days of preoperative tamoxifen. Breast 31:219-223
Gardiner, Jamie D; Abegglen, Lisa M; Huang, Xiaomeng et al. (2017) C/EBP?-1 promotes transformation and chemoresistance in Ewing sarcoma cells. Oncotarget 8:26013-26026
Ding, Yun; Fleming, Aaron M; Burrows, Cynthia J (2017) Sequencing the Mouse Genome for the Oxidatively Modified Base 8-Oxo-7,8-dihydroguanine by OG-Seq. J Am Chem Soc 139:2569-2572
Carleton, Julia B; Berrett, Kristofer C; Gertz, Jason (2017) Multiplex Enhancer Interference Reveals Collaborative Control of Gene Regulation by Estrogen Receptor ?-Bound Enhancers. Cell Syst 5:333-344.e5
Lai, Run-Zhi; Han, Xue-Sheng; Dahlquist, Frederick W et al. (2017) Paradoxical enhancement of chemoreceptor detection sensitivity by a sensory adaptation enzyme. Proc Natl Acad Sci U S A 114:E7583-E7591

Showing the most recent 10 out of 1113 publications